MedTrace Logo

Comparison of Intramuscular Injection From Two Different Sites in Children

NCT05279144 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2023-05-16

No results posted yet for this study

Summary

Administration of intramuscular injections (IM) is now common practice in pediatric clinical settings. For this reason, nurses should both update their clinical skills and provide evidence-based practices to children. The aim of this study; The aim of this study is to compare vastus lateralis (VL) and ventrogluteal (VG) region applications in terms of pain and fear in safe and evidence-based intramuscular injection application in children.

H0: There is no difference in terms of pain and fear between the children aged 4-6 years who received IM from the vastus lateralis (VL) region and those who received IM from the ventrogluteal (VG) region.

H1: Children between the ages of 4 and 6 years IM administered from the vastus lateralis (VL) region have higher pain than those administered IM from the ventrogluteal (VG) region.

H2: The fear of children aged 4-6 years who underwent IM from the vastus lateralis (VL) region is higher than that of children who were administered IM from the Ventrogluteal (VG) region.

Conditions

  • Application Site Infection

Interventions

OTHER

Ventroguleal

Vastus Lateralis

Sponsors & Collaborators

  • Sakarya University

    lead OTHER

Principal Investigators

  • DİLEK MENEKŞE, Assis prof. · Sakarya University

  • NURSAN ÇINAR, Proffesor · Sakarya University

  • BAHRİ ELMAS, Assoc Prof · Sakarya University

  • ÖNER ÖZDEMİR, Proffesor · Sakarya University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
4 Years
Max Age
6 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-25
Primary Completion
2022-05-30
Completion
2022-07-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05279144 on ClinicalTrials.gov